Clinical trials · New York
Advanced or Metastatic Solid Tumors clinical trials in New York
We’re tracking 582 recruiting advanced or metastatic solid tumors studies with a site in New York — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New York, New YorkAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
New York, New YorkAges 6 months–25 years - NCT07166601RecruitingPhase 1
Study of a drug for advanced solid tumors with MUC-1 marker
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
New York, New YorkAges 18 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT04412616RecruitingPhase 1
Study drug for advanced EGFR-positive solid tumors
This early-phase trial tests a new drug (ZZ06) in adults with advanced solid cancers that have an EGFR “positive” tumor test result. It’s for people whose cancer has grown despite standard treatment or who don’t have a standard option.
The Bronx, New YorkAges 18 years+ - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Ithaca, New YorkAges 18–99 - NCT06859762RecruitingPhase 1
Study of YL217 for advanced solid tumors
This study tests an experimental drug called YL217 in people with advanced solid tumors that have not responded to other treatments. The drug may work by targeting a protein on cancer cells and delivering a chemotherapy-like agent directly to the tumor, potentially slowing or stopping its growth.
New York, New YorkAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
New York, New YorkAges 18 years+ - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
New York, New YorkAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06463340RecruitingPhase 1
Study of SGR-3515 for advanced solid tumors
This trial tests a new drug called SGR-3515 for people with advanced solid tumors. It aims to see if the drug is safe and how it works in the body.
New York, New YorkAges 18 years+ - NCT06723236RecruitingPhase 1
Study of MGC028 for Advanced Solid Tumors
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06697197RecruitingPhase 1/Phase 2
Study of experimental drug BMS-986482 for advanced solid tumors
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT06667141RecruitingPhase 1/Phase 2
Study of ACR-2316 for advanced solid tumors
This trial is testing an experimental drug called ACR-2316 for people with certain advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug can shrink tumors or slow their growth.
The Bronx, New YorkAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
New York, New YorkAges 18 years+ - NCT06641908RecruitingPhase 1
Anti-GD2 drug M3554 for advanced solid tumors
This trial tests a new drug called M3554 that targets a protein (GD2) found on some cancer cells. It is for people whose cancer has not responded to standard treatments, including certain sarcomas and glioblastoma. The goal is to see if M3554 can shrink or stop the cancer.
New York, New YorkAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
New York, New YorkAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
New York, New YorkAges 18 years+ - NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
White Plains, New YorkAges 18 years+ - NCT06253130RecruitingPhase 1/Phase 2
Study of IMP1734 for Advanced Solid Tumors with HRR Mutations
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
Ithaca, New YorkAges 18–89 - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
New York, New YorkAges 18 years+
Advanced or Metastatic Solid Tumors trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- NYU Langone Health · 5 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 4 studies
- Memorial Sloan Kettering Cancer Center · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
- Cayuga Cancer Center
- Cayuga Medical Center
- Clinical Research Alliance, Inc
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in New York?
- Yes. We're currently tracking 582 recruiting advanced or metastatic solid tumors studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.